VRTX · Full Picture

VERTEX PHARMACEUTICALS INC / MA — the full picture

Earnings window · 2026-08-04 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Guidance and Outlook · Guidance & outlookPriority 96
    -28.1% operating_income; 4 sources (news, press_release, sec_filing, transcript); 7 forward row(s); quote_verified
    Vertex Pharmaceuticals raised its 2026 revenue guidance to US$13.10–US$13.20 billion.
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 93
    +49.2% assets; 4 sources (news, press_release, sec_filing, transcript); 8 forward row(s); quote_verified
    Vertex announced a planned acquisition of Crinetics Pharmaceuticals for approximately $10.0 billion to further expand its therapeutic portfolio.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 91
    +45.5% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 5 forward row(s); structured_verified
    Vertex reported Q3 2026 revenue of $3.44 billion, up 12% year over year, and raised full-year revenue guidance to $13.15 billion to $13.25 billion.
  4. Crinetics Acquisition Financing · M&A and divestituresPriority 87
    +18.2% assets; 2 sources (news, sec_filing); 6 forward row(s); structured_verified
    VERTEX PHARMACEUTICALS INC / MA acquired Crinetics Pharmaceuticals for an equity value of approximately $10.0 billion.
  5. Liquidity and Debt Position · Debt, leverage & refinancingPriority 84
    -0.6% liability; 3 sources (press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    Vertex raised $4.5 billion of term loans to fund part of the Crinetics acquisition; the loans currently bear interest at approximately 4.8%.
  6. Operating Expense Trends · Operating expenses (SG&A)Priority 82
    -7.7% operating_income; 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Vertex’s SG&A expenses increased 90% in the third quarter and 52% in the first nine months, primarily due to $203.0 million of Crinetics-related cash-settled equity award compensation and transaction costs, increased headcount, and commercial investment supporting JOURNAVX and a potential IgAN povetacicept launch.
  7. Product / Drug Pipeline Progress · Products & launchesPriority 79
    +11.2% revenue; 2 sources (news, transcript); 3 forward row(s); quote_verified
    Vertex said the recently acquired Crinetics portfolio including PALSONIFY and atumelnant are projected to reach $5 billion in peak sales.
  8. End-Market Demand Trends · Demand, orders & backlogPriority 69
    2 sources (news, sec_filing); 1 forward row(s); quote_verified
    Approximately 5,500 patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time with this approval
  9. Capital Return Program · Buybacks & dividendsPriority 68
    -3.2% cash; 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    Vertex had $2.5 billion remaining under the share repurchase program authorized by its Board in May 2025 as of September 30, 2026; the program has no expiration date, may be discontinued at any time and is expected to be funded with cash on hand and operating cash.
  10. Net Income and Profitability · Operating income & profitabilityPriority 65
    -13.4% net_income (realized); 2 sources (news, press_release); quote_verified
    Third-quarter 2026 GAAP net income was $654 million, compared with $1.1 billion in third-quarter 2025; the decline was primarily due to Crinetics acquisition expenses.
  11. Gross Margin Drivers · Gross marginPriority 59
    -3.3% operating_income (realized); 2 sources (sec_filing, transcript); 2 forward row(s); structured_verified
    Cost of sales in Q2 2026: $489.2 million, up 20% from $407.5 million in Q2 2025; cost of sales for six months ended June 30, 2026: $882.0 million, up 14% from $770.5 million
  12. Liquidity and Debt Position · UnclassifiedPriority 58
    quote_verified
    Vertex's acquisition of Crinetics resulted in the company carrying net debt for the first time in many years.

Threads by pillar

Revenue & Demand Priority 96 · 7 threads

Costs & Margins Priority 89 · 5 threads

Capital & Balance Sheet Priority 90 · 3 threads

Strategy & Portfolio Priority 96 · 4 threads

Legal, Regulatory & Policy Priority 70 · 5 threads

Guidance & Outlook Priority 96 · 1 thread

Macro & Market Conditions Priority 56 · 4 threads

Unclassified Priority 77 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
assets+67.5%+67.5%+61.2%
cash-46.6%+46.6%+18.1%
operating_income-36.4%+36.4%-16.6%
liability-7.1%+30.5%-27.5%
revenue+12.5%+12.5%+58.0%
net_income-4.1%+4.1%-12.2%
margin——-0.6%